Suchergebnisse - "Beijnen, Jos H"

PubPharm (1.947)

1

Acquired and intrinsic resistance to vemurafenib in BRAF^V600E-driven melanoma brain metastases

enthalten in: bioRxiv.org | 2024

von Zhang, P. | Kuil, L. | Buil, L. | +4

2

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood

enthalten in: Journal of pharmaceutical and biomedical analysis | 2024

von Schouten, W. | Roseboom, I. | Lucas, L. | +7

3

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum

enthalten in: Journal of pharmaceutical and biomedical analysis | 2024

von Buitelaar, P. | de Jong, K. | Aardenburg, L. | +4

4

Intradermal naked DNA vaccination by DNA tattooing for mounting tumor-specific immunity in stage IV melanoma patients : a phase I clinical trial

enthalten in: Oncology research and treatment | 2024

von Geukes Foppen, M. | Rohaan, M. | Borgers, J. | +6

5

Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice

enthalten in: Molecular pharmaceutics | 2024

von Loos, N. | Ferreira Martins, M. | Rijmers, J. | +5

6

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib

enthalten in: Toxicology and applied pharmacology | 2024

von Loos, N. | Sparidans, R. | Heydari, P. | +4

7

Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Loos, N. | Bui, V. | de Jong, D. | +4

8

Are novel oral oncolytics underdosed in obese patients?

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Lin, L. | van der Meer, E. | Steeghs, N. | +2

9

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

enthalten in: Therapeutic drug monitoring | 2024

von Lin, L. | Barkman, H. | Smit, E. | +4

10

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

enthalten in: Journal of clinical pharmacology | 2024

von van der Heijden, L. | Ribbers, C. | Vermunt, M. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[195]